GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medincell SA (XPAR:MEDCL) » Definitions » Short Interest

Medincell (XPAR:MEDCL) Short Interest


View and export this data going back to 2018. Start your Free Trial

What is Medincell Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Medincell's Short Interest

For the Biotechnology subindustry, Medincell's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medincell's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medincell's Short Interest distribution charts can be found below:

* The bar in red indicates where Medincell's Short Interest falls into.


Medincell (XPAR:MEDCL) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medincell SA (XPAR:MEDCL) » Definitions » Short Interest
Comparable Companies
XPAR:AELIS XPAR:IVA XPAR:GNFT XPAR:IPH XPAR:TNG XPAR:DBV XPAR:NANO XPAR:ALSEN XPAR:ADOC XPAR:OSE OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
MEB:Germany
Address
3 rue des Freres Lumiere, Jacou, FRA, 34830
Website
https://www.medincell.com
Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.

Medincell (XPAR:MEDCL) Headlines

No Headlines